Results 71 to 80 of about 47,533 (300)

Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells

Oncology Reports, 2011
In spite of an initially promising anti-tumor activity, oxaliplatin-based combinatorial treatments can eventually result in a tumor resistance response. In this study we aimed to understand the role of autophagy in HCC cell resistance to oxaliplatin and to discuss its potential therapeutic implication. We found
Hailei, Du, Weiping, Yang, Lin, Chen, Mingming, Shi, Varun, Seewoo, Jiayu, Wang, Andy, Lin, Zhuoran, Liu, Weihua, Qiu   +8 more
openaire   +3 more sources

HOTAIR/miR-1277-5p/ZEB1 axis mediates hypoxia-induced oxaliplatin resistance via regulating epithelial-mesenchymal transition in colorectal cancer

Cell Death Discovery, 2022
The hypoxic microenvironment contributes to the chemoresistance of many malignant tumors including colorectal cancer (CRC). Accumulating studies have indicated that long non-coding RNAs (lncRNAs) play important roles in chemotherapy resistance.
Xingyue Weng, Hao Liu, Jian Ruan, Miaoyan Du, Lingjie Wang, Jiayan Mao, Ying Cai, Xuemei Lu, Wei Chen, Yaqing Huang, Xiao Zhi, Jianzhen Shan   +11 more
doaj   +1 more source

Understanding cisplatin resistance using cellular models [PDF]

, 2007
Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, Mary W., Stordal, Britta
core   +2 more sources

ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin.

European review for medical and pharmacological sciences, 2020
The purpose of this study was to explore the role of ANXA3 in lung cancer cell resistance to oxaliplatin (OXA).After adding different concentrations of Ox, A549, and A549/Ox cell viability were examined using cell counting kit-8 (CCK-8) assay, and the mRNA and protein expressions of ANXA3 were analyzed by quantitative Real Time-Polymerase Chain ...
Jin, Y.-F., Huang, Y.-T., Chen, P.-F.
openaire   +2 more sources

Role of AMPK in Regulation of Oxaliplatin-Resistant Human Colorectal Cancer

Biomedicines, 2022
Oxaliplatin is a platinum analog that can interfere with DNA replication and transcription. Continuous exposure to oxaliplatin results in chemoresistance; however, this mechanism is not well known. In this study, oxaliplatin-resistant (OR) colorectal cancer (CRC) cells of HCT116, HT29, SW480 and SW620 were established by gradually increasing the drug ...
Sun Young Park, Ye Seo Chung, So Yeon Park, So Hee Kim   +3 more
openaire   +3 more sources

Unusual DNA binding modes for metal anticancer complexes [PDF]

, 2009
DNA is believed to be the primary target for many metal-based drugs. For example, platinum-based anticancer drugs can form specific lesions on DNA that induce apoptosis.
Pizarro, Ana M., Sadler, P. J.
core   +1 more source

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma. [PDF]

, 2016
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas.
DuBois, Steven G, Matthay, Katherine K, Vo, Kieuhoa T   +2 more
core   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source

Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance [PDF]

, 2015
Current standard treatments for metastatic colorectal cancer (CRC) are based on combination regimens with one of the two chemotherapeutic drugs, irinotecan or oxaliplatin.
Andersen, Claus L., Beck, Mette Kristina, Belling, Kirstine C., Bosman, Fred, Brünner, Nils, Budinská, Eva, Delorenzi, Mauro, Gupta, Ramneek, Hansen, Tine P., Hanáková, Barbora, Jensen, Niels F., Moreira, José M.A., Nguyen Do, Khoa, Nygård, Sune B., Pfeiffer, Per, Rasmussen, Mads H., Roth, Arnaud, Rømer, Maria U., Stenvang, Jan, Tarpgaard, Line S., Tejpar, Sabine, Viuff, Birgitte   +21 more
core   +5 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source